Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes

Rationale & Objective: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been approved for type 2 diabetes (T2D) and obesity. However, the real-world utilization of tirzepatide remains unexplored, particularly in patients with chronic kidney disease (CKD), where the prevalence of T2D and o...

Full description

Saved in:
Bibliographic Details
Main Authors: Panupong Hansrivijit, Janinne Ortega-Montiel, Deborah J. Wexler, Elisabetta Patorno, Julie M. Paik
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Kidney Medicine
Subjects:
GIP/GLP-1
chronic kidney disease
type 2 diabetes
adult obesity
prescribing trends
SGLT2 inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2590059525000494
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590059525000494

Similar Items